- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06316427
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma
March 22, 2024 updated by: Jing Pan, Beijing GoBroad Hospital
Autologous and Donor-derived CD7 CAR T-cell Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma: a Single-center, Open-label, Phase Ⅰ/Ⅱ Clinical Trial
This is a single-center, open-label, non-randomized, phase I/II trial.
Patients with refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) will receive autologous, prior-HSCT donor-derived or new donor-derived CD7 CAR T cells according to their HSCT history, peripheral blood leukemia burden and at their discretion.
The primary objective is to learn about the safety of autologous, prior-HSCT donor-derived and new donor-derived CD7 CAR T-cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia and lymphoma (r/r T-ALL/T-LBL) in phase I and to learn about the efficacy of autologous, prior-HSCT donor-derived and new donor-derived CD7 CAR T-cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia and lymphoma (r/r T-ALL/T-LBL) in phase II.
The primary endpoint is type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR T-cell infusion in phase I and overall response rate (ORR), which includes CR, CRh, CRi, MLFS, aplastic marrow for blood and bone marrow; central nervous system (CNS) remission; CR and PR for lymphomatous extramedullary disease according to National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia at 3 months (± 1 week) post CD7 CAR T-cell infusion in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells in phase II.
A total number of 80 subjects will be enrolled.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tengyu Wang
- Phone Number: 86+18333186020
- Email: tengyu.wang@gohealtharo.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 102206
- Recruiting
- Beijing GoBroad Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Only patients who meet all the following criteria can be included in the group:
- CD7-positive refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) with progression or intolerance after all standard treatments, limited prognosis from currently available treatments and no available treatment options (e.g. HSCT or chemotherapy).
- Tumor cells in bone marrow or cerebrospinal fluid are positive for CD7 antigen by flow cytometry or tumour tissue is positive for CD7 by immunohistochemistry (CD7 antigen positivity by flow cytometry: >80% of tumour cells expressing CD7 with a mean fluorescence intensity [MFI] of CD7 similar to that of normal T cells are considered to have fully positive expression; >80% of tumor cells expressing CD7 but with an MFI of CD7 at least 1 log lower than that of normal T cells are considered to have low expression [dim]; tumor cells with a CD7 expression rate between 20-80% are considered to have partial expression; CD7 antigen positivity by pathological immunohistochemistry: >30%);
- Male or female, age 1-70 years;
- No severe allergic constitution;
- Eastern Cooperative Oncology Group (ECOG) performance status score (Oken et al., 1982) of 0-2;
- Life expectancy of at least 60 days as determined by the investigator;
- Provide a signed informed consent form prior to any screening procedures; subjects volunteering to participate in the study should be capable of understanding and signing the informed consent form and be willing to follow the study visit schedule and associated study procedures as specified in the protocol. Subjects aged 19-70 years old need to be sufficiently aware and capable of signing the informed consent form; subjects aged 1-7 years can be recruited after legal guardians or patient advocates sign the informed consent form; subjects aged 8-18 years need to be sufficiently aware and able to sign the informed consent form, and their legal guardians or patient advocates also need to sign the informed consent form.
Exclusion Criteria:
Patients with at least one of the following conditions are excluded:
- Intracranial hypertension or unconscious;
- Acute heart failure or severe arrhythmia;
- Acute respiratory failure;
- Other types of malignant tumors;
- Diffuse intravascular coagulation;
- Serum creatinine and/or blood urea nitrogen over 1.5 times the normal value;
- Sepsis or other uncontrolled infection;
- Uncontrolled diabetes mellitus;
- Severe psychological disorder;
- Obvious cranial lesions by cranial MRI;
- Allergic constitution;
- Organ recipients;
- Pregnant or breastfeeding;
- Active, uncontrolled infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or treponema pallidum (TP).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm-1
Autologous CD7 CAR T-cell treatment
|
Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
|
Experimental: Arm-2
Prior-HSCT donor-derived CD7 CAR T-cell treatment
|
Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
|
Experimental: Arm-3
New donor-derived CD7 CAR T-cell treatment
|
Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Limiting Toxicity (DLT) in phase I
Time Frame: 21 days post infusion
|
Type and incidence of dose-limiting toxicity (DLT) within 21 days after CD7 CAR T-cell infusion
|
21 days post infusion
|
Overall Response Rate (ORR) in phase II
Time Frame: 3 months (± 1 week) post infusion
|
Overall response rate (ORR), which includes CR, CRh, CRi, MLFS, aplastic marrow for blood and bone marrow; central nervous system (CNS) remission; CR and PR for lymphomatous extramedullary disease per National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia at 3 months (± 1 week) post CD7 CAR T-cell infusion in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells
|
3 months (± 1 week) post infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR) in phase I
Time Frame: 3 months (± 1 week) post infusion
|
Overall response rate (ORR), which includes CR, CRh, CRi, MLFS, aplastic marrow for blood and bone marrow; central nervous system (CNS) remission; CR and PR for lymphomatous extramedullary disease per National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia at 3 months (± 1 week) post CD7 CAR T-cell infusion in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells
|
3 months (± 1 week) post infusion
|
Safety in phase II
Time Frame: 2 years post infusion
|
The adverse events in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells will be assessed according to the 2019 Consensus on Cytokine Release Syndrome and Immune-cell-associated Neurotoxicity published by the American Society of Transplantation and Cell Therapy (ASTCT), the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and EBMT 2019 consensus.
|
2 years post infusion
|
Progression-Free Survival (PFS) in phase II
Time Frame: 2 years post infusion
|
Progression-free survival (PFS) in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells.
|
2 years post infusion
|
Duration of Remission (DOR) in phase II
Time Frame: 2 years post infusion
|
Duration of remission (DOR) in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells.
|
2 years post infusion
|
Overall Survival (OS) in phase II
Time Frame: 2 years post infusion
|
Overall survival (OS) in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells.
|
2 years post infusion
|
Levels of CD7 CAR-T Cells in phase II
Time Frame: 2 years post infusion
|
Levels of CD7 CAR-T cells in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells
|
2 years post infusion
|
Levels of CAR transgene in phase II
Time Frame: 2 years post infusion
|
Levels of CAR transgene in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells
|
2 years post infusion
|
Levels of immune cells in phase II
Time Frame: 2 years post infusion
|
Levels of immune cells in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells
|
2 years post infusion
|
Levels of cytokines in phase II
Time Frame: 2 years post infusion
|
Levels of cytokines in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells
|
2 years post infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2024
Primary Completion (Estimated)
April 1, 2026
Study Completion (Estimated)
March 30, 2028
Study Registration Dates
First Submitted
March 8, 2024
First Submitted That Met QC Criteria
March 14, 2024
First Posted (Actual)
March 18, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 22, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BJGBYY-IIT-LCYJ-2024-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia, in Relapse
-
Institut Paoli-CalmettesINATHERYSRecruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia RecurrentFrance
-
Federal Research Institute of Pediatric Hematology...RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in RelapseRussian Federation
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Andrew E. Place, MDUniversity of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaboratorsRecruitingAcute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditionsUnited States
-
Group for Research in Adult Acute Lymphoblastic...AmgenUnknownAcute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed RemissionFrance
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
St. Jude Children's Research HospitalActive, not recruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, RefractoryUnited States
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic LeukemiaFrance
-
Chongqing Precision Biotech Co., LtdRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
Clinical Trials on Autologous CD7 CAR T-cell
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAutoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still DiseaseChina
-
Guangzhou Bio-gene Technology Co., LtdActive, not recruitingT-Cell Acute Lymphocytic LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNeoplasms | Hematologic DiseasesChina
-
Ying WangRecruiting
-
Shenzhen University General HospitalRecruiting
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingCD7+ Acute Leukemia | CD7+ LymphomaChina
-
Bioceltech Therapeutics, Ltd.RecruitingT Cell Lymphoblastic LymphomaChina
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/LymphomaChina